Aranda Pharma Overview
- Year Founded
-
2015

- Status
-
Private
- Employees
-
5

- Latest Deal Type
-
Crowdfunding
- Latest Deal Amount
-
$790K
- Investors
-
3
Aranda Pharma General Information
Description
Developer of novel antiandrogen drugs intended to combat prostate cancer and neurodegenerative diseases. The company's drugs are made of small molecules and androgen receptor antagonists that are non-toxic, and provide effective treatments for hair loss and acne, which are underrepresented drug targets despite being validated without affecting hormonal function in other parts of the body, enabling clients to improve the quality of life for millions of people suffering from hair loss and acne.
Contact Information
Website
www.arandapharma.comCorporate Office
- Haartmaninkatu 4
- Terkko Health Hub, Building 14
- 00290 Helsinki
- Finland
Corporate Office
- Haartmaninkatu 4
- Terkko Health Hub, Building 14
- 00290 Helsinki
- Finland
Aranda Pharma Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Equity Crowdfunding | 30-Dec-2021 | $790K | Completed | Pre-Clinical Trials | ||
2. Early Stage VC | 21-May-2018 | Completed | Startup | |||
1. Seed Round | 04-Nov-2015 | Completed | Startup |
Aranda Pharma Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary Shares |
Aranda Pharma Patents
Aranda Pharma Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-9827249-B2 | Use of condensed benzo[b]thiazine derivatives as cytoprotectants | Active | 31-May-2013 | ||
ES-2715877-T3 | Use of fused benzo [b] thiazine derivatives as cytoprotectors | Active | 31-May-2013 | ||
US-20160106754-A1 | Use of condensed benzo[b]thiazine derivatives as cytoprotectants | Active | 31-May-2013 | ||
EP-3004118-A1 | Use of condensed benzo[b]thiazine derivatives as cytoprotectants | Active | 31-May-2013 | ||
EP-3004118-B1 | Use of condensed benzo[b]thiazine derivatives as cytoprotectants | Active | 31-May-2013 | A61K31/542 |
Aranda Pharma Signals
Aranda Pharma Investors (3)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Innovestor | Venture Capital | Minority | ||
Finnvera | Lender/Debt Provider | Minority | ||
Tarrex Biopharma | Corporation | Minority |
Aranda Pharma FAQs
-
When was Aranda Pharma founded?
Aranda Pharma was founded in 2015.
-
Where is Aranda Pharma headquartered?
Aranda Pharma is headquartered in Helsinki, Finland.
-
What is the size of Aranda Pharma?
Aranda Pharma has 5 total employees.
-
What industry is Aranda Pharma in?
Aranda Pharma’s primary industry is Drug Discovery.
-
Is Aranda Pharma a private or public company?
Aranda Pharma is a Private company.
-
What is Aranda Pharma’s current revenue?
The current revenue for Aranda Pharma is
. -
How much funding has Aranda Pharma raised over time?
Aranda Pharma has raised $2.42M.
-
Who are Aranda Pharma’s investors?
Innovestor, Finnvera, and Tarrex Biopharma have invested in Aranda Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »